🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Michael Timonian

Broad Institute

ORCID: 0000-0002-1014-3502

Also affiliated with Harvard University, Dana-Farber Cancer Institute

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone”.

Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone

medRxiv(2024)10.1101/2024.04.19.24306082

N/A

0.343DataRank · unranked

6 citations

Michelle P. Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D. Lightbody +17 more

Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial

Nature Communications(2025)10.1038/s41467-024-55308-5

N/A

0DataRank · unranked

14 citations

Michelle P. Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D. Lightbody +17 more

Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0)

Research Square(2025)10.21203/rs.3.rs-6696313/v1

N/A

0DataRank · unranked

0 citations

Daniel L. Schwartz, Susanna Gentile, K. Elias, Tulika Gupta, Jacqueline Perry +43 more